Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Change in Accured Expenses came in at $61.6 million in Q2 2026, down 61.06% YoY from $158.2 million in Q2 2025, and up 135.0% on a QoQ basis from -$176.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Change in Accured Expenses data on file, last reported at $61.6 million in Q2 2026.
- Quarterly Change in Accured Expenses fell 61.06% year-over-year to $61.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$39.8 million (down 281.27% YoY) and the FY2025 annual result came in at $75.1 million, down 17.59% from the prior year.
- Change in Accured Expenses climbed to $61.6 million in Q2 2026, from -$176.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $249.4 million in Q3 2025 to a low of -$176.0 million in Q1 2026.
- A 5-year average of $18.0 million and a median of $64.9 million in 2022 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 198.38% in 2025, down 3142.24% in 2025.
- Tracing ALNY's Change in Accured Expenses over 5 years: stood at $102.6 million in 2022, then tumbled by 137.68% to -$38.7 million in 2023, then slumped by 60.62% to -$62.1 million in 2024, then plunged by 181.54% to -$174.9 million in 2025, then surged by 135.24% to $61.6 million in 2026.
- The last three Change in Accured Expenses figures came in at $61.6 million (Q2 2026), -$176.0 million (Q1 2026), and -$174.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -13.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.62 Mn |
| Jun 30, 2026 | 61.62 Mn |
| Mar 31, 2026 | -176.03 Mn |
| Mar 31, 2026 | -176.03 Mn |
| Dec 31, 2025 | -174.85 Mn |
| Dec 31, 2025 | -174.85 Mn |
| Sep 30, 2025 | 223.51 Mn |
| Sep 30, 2025 | 223.51 Mn |
| Jun 30, 2025 | 184.15 Mn |
| Jun 30, 2025 | 184.15 Mn |
| Mar 31, 2025 | -157.74 Mn |
| Mar 31, 2025 | -157.74 Mn |
| Dec 31, 2024 | -62.11 Mn |
| Dec 31, 2024 | -62.11 Mn |
| Sep 30, 2024 | 83.60 Mn |
| Sep 30, 2024 | 83.60 Mn |
| Jun 30, 2024 | 74.47 Mn |
| Jun 30, 2024 | 74.47 Mn |
| Mar 31, 2024 | -4.87 Mn |
| Mar 31, 2024 | -4.87 Mn |